Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Subacute Toxicity Study of Nicotinamide Mononucleotide via Oral Administration
Jalan R, Olde Damink SW, Hayes PC, Deutz NE, Lee A
Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al
PT-141 (Bremelanotide) Dosing in Hepatic Impairment At a glance Standard dose / 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity Mild hepatic impairment (Child-Pugh A) / no dose adjustment required per FDA labeling Moderate hepatic impairment (Child-Pugh B) / no dose adjustment required
Makarewicz M, Drod I, Tarko T, Duda-Chodak A
US$ 23.57
US$ 22.02
US$ 24.38
US$ 28.58
US$ 25.36
US$ 21.59
US$ 27.54
